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Introduction
In renal transplant recipients Parvovirus B19 (PB19)
infection can lead to severe anaemia, due to lytical
replication within erythroid progenitor cells. Clearance
of PB19-infection and protective immunity is assumed
to be provided by specific PB19-IgG-antibodies [1].
In fact, passive transfer of PB19-IgG-antibodies by
means of intravenous immunoglobulin (IvIg) prepara-
tions is successfully used to treat PB19-related anaemia
[1,2]; however, several reports have shown that PB19-
related anaemia can recur despite treatment with
IvIg [2–11].
In this report we describe in detail a renal transplant
patient who experienced relapsing severe PB19-related
anaemia and we reviewed the current literature regard-
ing factors associated with relapsing disease. Our data
suggest that primary PB19-infection after kidney
transplantation and polyclonal T-cell depleting thera-
pies are risk factors for relapsing PB19-related anaemia.
In addition, they support the concept that a PB19-
specific cellular immune response is critical to control
PB19-infection and establish protective immunity.
Case report
The course of haemoglobin/reticulocytes, PB19-
serology/PCR, immunosuppression, and therapy
for PB19-infection is summarized in Figure 1. This
32-year-old female patient with end-stage renal disease
due to Alport’s syndrome received a renal transplant
from her father. Initial immunosuppression consisted
of tacrolimus, mycophenolate-mofetil, prednisone and
basiliximab, given on days 0 and 4. On day 4 post-
transplant, she experienced antibody-mediated rejec-
tion, which was successfully treated with high-dose
steroids and a polyclonal anti-T-lymphocyte globulin
(ATG). Subsequently, the patient developed anaemia,
which was assumed to be related to ATG and four
blood transfusions were given [12]. However, haemo-
globin dropped again to 68 g/l with marked reticulocy-
topenia (10 109/l, normal range 40–140 109/l).
Further investigations revealed a positive PB19-PCR
in serum (log 6.8 copies/ml), weak positive PB19-
IgM-antibodies (1.5; positive >1.0) and PB19-
IgG-antibodies (1.9; positive >1.0). Retrospectively,
the recipient had negative PB19-IgG-antibodies (<0.8)
and PB19-PCR pre-transplant. The kidney donor had
negative PB19-PCR, negative PB19-IgM (<0.8) but
positive PB19-IgG-antibodies (1.9), consistent with
immunity to PB19 without viraemia. Furthermore,
all blood transfusions the patient had received were
tested negative by PB19-PCR. Therefore, our patient
had community-acquired primary PB19-infection.
After therapy with IvIg (cumulative dose 150 g) a
prominent increase in reticulocyte counts was observed
and anaemia resolved, while PB19-viraemia persisted
despite high levels of PB19-IgG-antibodies passively
transferred through IvIg. Three and a half months
after treatment with IvIg, anaemia with reticulocyto-
penia recurred and two blood transfusions were given.
At this time point PB19-viraemia was log 7.0 copies/ml
and PB19-IgG-antibodies became negative again.
Bone marrow biopsy confirmed the diagnosis of
relapsing PB19-infection by the presence of giant
proerythroblasts and a positive PB19-PCR. A second
course of IvIg (cumulative dose 125 g) was given,
which was again followed by an increase of
reticulocyte counts and resolution of anaemia.
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Concurrently, baseline immunosuppression was
further reduced (tacrolimus trough levels from
8–15 ng/ml to 6–8 ng/ml, mycophenolate-mofetil dose
from 1 g/day to 0.5 g/day).
Within the next 18 months, anaemia did not recur
and reticulocyte counts were mostly in the normal
range. PB19-IgG-antibody levels again became nega-
tive 4 months after the second IvIg course. Thereafter,
PB19-IgG-antibody levels continuously increased with
transient high levels of PB19-IgM-antibodies consis-
tent with recipient-derived production. However,
despite considerable levels of PB19-IgG-antibody
levels over 9 months (February 2006 to November
2006), PB19-viraemia persisted between log 3.6 and
4.8 copies/ml under dual immunosuppression consist-
ing of tacrolimus (trough levels to 4–6 ng/ml) and
mycophenolate-mofetil (0.5 g/day).
Renal allograft function recovered after the early
rejection episode and remained stable during the 2-year
follow-up, with an actual serum creatinine of
132 mmol/ml (estimated glomerular filtration rate
51ml/ml) and no proteinuria.
Review of the literature
Medline search between 1986 and 2006 yielded 49
kidney transplant recipients with PB19-related anae-
mia and follow-up data on relapsing disease
(Supplementary table 1). We extracted data on primary
PB19-infection, baseline immunosuppression, induc-
tion therapy, therapy of first PB19-related anaemia
episode, clinical response to therapy (i.e. haemoglobin
recovery), virological response to therapy (i.e. clear-
ance of PB19-viraemia), relapse of PB19-related
anaemia and therapy of second PB19-related anaemia
episode. Overall, the percentage of missing data was
substantial (primary PB19-infection: 73%, baseline
immunosuppression: 33%, induction therapy: 35%,
therapy of first PB19-related anaemia episode: 10%,
clinical response to therapy (i.e. haemoglobin recov-
ery): 16%, virological response to therapy
(i.e. clearance of PB19-viraemia): 67%) limiting the
validity of the following analysis.
Relapsing PB19-related anaemia was observed in
16/49 patients (33%). Thirty-nine of 44 patients (89%)
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Fig. 1. Immunosuppression and therapy with intravenous immunoglobulin (IvIg), Parvovirus B19 (PB19)-serology and viraemia,
haemoglobin and reticulocyte counts from November 2004 to November 2006. PB19-serology was performed by use of the PB19-IgG/
IgM-EIA (Denka Seiken). PB19-IgM-antibodies >1.0 and PB19-IgG-antibodies >1.0 are considered positive. Qualitative and quantitative
real-time PB19-PCR was performed as described previously [15]. Normal reticulocyte counts range from 40 to 140 109/l. ATG, polyclonal
anti-T-lymphocyte globulin; MMF, mycophenolate-mofetil.
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with recorded therapy for the first PB19-related
anaemia episode received IvIg, while in four patients
only, baseline immunosuppression was reduced (i.e.
azathioprine or mycophenolate-mofetil). Relapsing
anaemia was observed more often in patients with
primary PB19-infection (8/13 patients (62%) vs 8/36
patients (22%); P¼ 0.02). Data on induction therapy
was recorded in 32/49 patients (65%). Nineteen of 32
patients (59%) received no induction therapy, while 13
patients had different induction agents [ATG (n¼ 7),
ALG (n¼ 2), IL-2 receptor blockers (n¼ 3), OKT3
(n¼ 1)]. Relapsing anaemia was observed more often
in patients having received ATG [ATG: 6/7 patients
(86%); other induction agents: 2/6 patients (33%); no
induction: 6/19 patients (32%); P¼ 0.04]. There
were no significant associations between relapsing
PB19-related anaemia and baseline immunosuppres-
sion (P¼ 0.17) therapy of first PB19-related anaemia
episode (P¼ 0.28), clinical response to therapy
(P¼ 0.32) and virological response to therapy
(P¼ 0.98).
Discussion
IvIg is widely used to treat PB19-related anaemia
because it contains high amounts of neutralizing PB19-
IgG-antibodies [1,2]. Indeed, the humoral immune
response is regarded as the major mechanism respon-
sible for clearance of PB19-infection [13]. Our case
demonstrates that treatment with IvIg is in fact
followed by a marked increase of reticulocyte
counts and a reduction of PB19-viraemia. However,
these passively transferred antibodies were unable to
control PB19-infection. This observation suggests
that PB19 persists in the intracellular compartment
(e.g. erythroid progenitor cells), which is not acces-
sible to antibodies, and that a PB19-specific cellular
immune response is required to control and clear the
infection. In this context, longitudinal analysis of
PB19-specific CD4 and CD8 T-cells would have been
of particular interest in the reported case, but were not
available [14].
Nevertheless, there is indirect evidence that T-cells
are of critical importance to control and clear PB19-
infection. First, relapse of PB19-related anaemia was
common (16/49 patients; 33%) despite treatment with
IvIg and relapsing disease was associated with T-cell
depleting therapy (i.e. ATG). Second, our case and
several other reports indicate that PB19-infection
was better controlled after reduction of therapies
suppressing preferably T-cells (e.g. calcineurin-
inhibitors) [7,8,10]. Third, Isa et al [14]. found a high
frequency of activated PB19-specific CD8 T-cells
beyond the first year after infection, despite resolution
of clinical symptoms and control of viraemia in healthy
individuals. This long-lasting CD8 T-cells response
indicates a significant function of the cellular immune
response to control and possibly clear PB19-infection.
Indeed, the observed enduring activated CD8 T-cell
response may be due to persistence of low amounts
of PB19 in intracellular compartments (e.g. in ery-
throid progenitor cells). However, it is as yet unknown
whether PB19 is completely cleared from the
human host or whether true latency exists, as known
for many viruses (e.g. herpesvirus family, polyoma-
virus BK) [14].
Our observation may also have implications for
clinical management of patients with PB19-related
anaemia. Patients with primary PB19-infection and/or
therapies with T-cell depleting antibodies are at
increased risk for relapsing disease. Therefore, such
patients should be closely monitored when the
protective effect of IvIg vanishes about 3 months
after therapy. Furthermore, baseline immunosuppres-
sion should be carefully lowered to improve the
potential of the immune systems to mount a sufficient
response to control PB19-infection.
In conclusion, primary PB19-infection and poly-
clonal T-cell depletion therapies are risk factors for
relapsing severe PB19-related anaemia, which may
require repetitive treatments with IvIg. In addition,
our data suggest that development of a PB19-specific
cellular immune response is essential to control
PB19-infection and establish protective immunity.
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